– USA, CA – Diomics announced today that Matthew J. Safaii, Founder and Managing Partner at Arrowroot Capital, has joined the company’s board of directors, effective immediately.
“Matt has advised and invested in many successful early-stage innovation companies,” said John F. Steel, Diomics CEO. “With his significant experience and skills, we look forward to his valuable contributions.”
Mr. Safaii currently serves as Managing Partner of Arrowroot Capital, a growth equity firm based in Santa Monica, CA, that invests in growing healthy, recurring revenue, software-as-a-service and internet-based businesses. Since 2003, Mr. Safaii has been an active investor in emerging technology companies in the US and Europe. He currently sits on the boards of Mednet Solutions, EIQ Networks, and 4Tell Solutions, and is an advisor to several companies such as Arrowroot Advisors and PromptMed Urgent Care.
“I am thrilled to join Diomics’ board. They are emerging as a leader in DNA collection technologies, and are expected to contribute meaningfully to forensics and diagnostics,” said Mr. Safaii. “I look forward to working with John and the team.”
Mr. Safaii received a B.A. in finance and marketing from Boston College and an M.B.A. from the Wharton School of the University of Pennsylvania.
About Diomics, Inc.
Diomics is focused on life sciences, specifically diagnostics, forensics, integrated DNA analysis, and genetic solutions. Our proprietary Diomat™ technology platform has the ability to efficiently pick up biologic materials from a variety of surfaces and release the majority of the DNA from the sample into the solution. The versatile characteristics of Diomat™ lend itself to a variety of product formats, including swabs, films, and fibers. Based in San Diego, California, Diomics has developed numerous products, tools, and services for the molecular diagnostic and forensic industries.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.